Literature DB >> 17305677

Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy.

Brian K Bevacqua1, Maher Fattouh, Misha Backonja.   

Abstract

Intraspinal clonidine is an effective adjunct to intrathecal/epidural opioid administration. We report a case of neuropathic pain treated with intraspinal analgesics in which depression, insomnia, and night terrors developed in association with intraspinal clonidine.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17305677     DOI： 10.1111/j.1533-2500.2007.00108.x

Source DB:  PubMed          Journal:  Pain Pract        ISSN： 1530-7085            Impact factor:   3.183


  5 in total

Review 1.  Intrathecal Analgesia for Chronic Refractory Pain: Current and Future Prospects.

Authors:  Catherine Smyth; Nadera Ahmadzai; Jason Wentzell; Ashley Pardoe; Andrew Tse; Tiffany Nguyen; Yvette Goddard; Shona Nair; Patricia A Poulin; Becky Skidmore; Mohammed T Ansari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  Intrathecal therapy for chronic pain: current trends and future needs.

Authors:  Salim M Hayek; Michael C Hanes
Journal:  Curr Pain Headache Rep       Date:  2014-01

3.  Somnambulism associated with the use of clonidine: A case report and review of the literature.

Authors:  Anupam Mitra; Samidha Tripathi; Gargi Bhattacharya; Pradipta Majumder
Journal:  Indian J Psychiatry       Date:  2018 Jul-Sep       Impact factor: 1.759

Review 4.  Intrathecal Drug Delivery: Advances and Applications in the Management of Chronic Pain Patient.

Authors:  Jose De Andres; Salim Hayek; Christophe Perruchoud; Melinda M Lawrence; Miguel Angel Reina; Carmen De Andres-Serrano; Ruben Rubio-Haro; Mathew Hunt; Tony L Yaksh
Journal:  Front Pain Res (Lausanne)       Date:  2022-06-16

Review 5.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.